Novel therapeutic approaches for non-small cell lung cancer: an updated view DOI

Niloufar Orooji,

Shabnam Babaei,

Manouchehr Fadaee

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 29

Опубликована: Апрель 5, 2025

Non-small cell lung cancer (NSCLC) continues to be one of the leading causes cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, targeted therapy adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved way for innovative therapeutic approaches that target specific genetic mutations promote immune response against tumor cells. This review explores emerging therapies, including therapies tyrosine kinase inhibitors (TKIs) actionable (e.g., EGFR, ALK, ROS1), well role checkpoint (ICIs) employ body's system combat cancer. Additionally, we discuss potential exosome promising nanotherapeutic options treatment NSCLC. study attempts provide a thorough overview changing landscape NSCLC its implications enhancing patient outcomes by presenting these techniques.

Язык: Английский

Novel therapeutic approaches for non-small cell lung cancer: an updated view DOI

Niloufar Orooji,

Shabnam Babaei,

Manouchehr Fadaee

и другие.

Journal of drug targeting, Год журнала: 2025, Номер unknown, С. 1 - 29

Опубликована: Апрель 5, 2025

Non-small cell lung cancer (NSCLC) continues to be one of the leading causes cancer-related mortality globally. Most patients who undergo surgical procedures may encounter distant metastasis or local recurrence, necessitating supplementary treatments such as radiation therapy, chemotherapy, targeted therapy adjuvant alternatives. Recent advancements in molecular biology and immunotherapy have paved way for innovative therapeutic approaches that target specific genetic mutations promote immune response against tumor cells. This review explores emerging therapies, including therapies tyrosine kinase inhibitors (TKIs) actionable (e.g., EGFR, ALK, ROS1), well role checkpoint (ICIs) employ body's system combat cancer. Additionally, we discuss potential exosome promising nanotherapeutic options treatment NSCLC. study attempts provide a thorough overview changing landscape NSCLC its implications enhancing patient outcomes by presenting these techniques.

Язык: Английский

Процитировано

0